It has long been recognized that COPD is a systemic disease in which several extrapulmonary manifestations, including cachexia and skeletal muscle dysfunction, contribute to morbidity and mortality. Functionally, skeletal muscle dysfunction in COPD patients is characterized by significant reduction in muscle strength and endurance. It is structurally characterized by loss of muscle mass and cross-sectional area (muscle atrophy), fiber type distribution (reduction in the proportion of oxidative fibers and increases in the proportion of glycolytic fibers), oxidative metabolic capacity (attenuation of mitochondrial enzyme activities and expression) and capillary distribution (significant loss of capillary density). Although disuse and inactivity are important contributors to the pathogenesis of skeletal muscle dysfunction in COPD patients, several other systemic and local factors are also involved. These include systemic inflammation, malnutrition, corticosteroid usage, hypoxemia, aging, smoking and local factors such as the production of reactive oxygen (ROS) and nitrogen species (RNS) and enhanced protein degradation inside muscle fibers, a result of increased activities of the proteasomal and lysosomal pathways and activation of calpains and caspases.

Evidence of skeletal muscle dysfunction in patients with COPD
=============================================================

It has been well established that skeletal muscle function (strength and endurance) and structure (fiber size, fiber type distribution, capillary density and metabolic capacity) are altered in patients with COPD. Specific abnormalities of these muscles include depressed muscle strength, reduction in muscle endurance, muscle fiber atrophy, and fiber type shift.

Depressed muscle strength
-------------------------

Alterations in muscle strength (defined as the capacity of the muscle to generate force) in COPD patients primarily involves the lower limb muscles, with quadriceps femoris muscle strength being 20% to 30% lower in patients with moderate to severe COPD as compared to control subjects ([@b64-copd-3-637]; [@b18-copd-3-637]; [@b52-copd-3-637]). The degree of reduced limb muscle strength correlates with the severity of the disease process ([@b18-copd-3-637]) ([Figure 1](#f1-copd-3-637){ref-type="fig"}). In addition, it has been well established that reduced limb muscle strength in patients with moderate COPD contributes to poor exercise performance, increased dyspnea and worsening of quality of life ([@b64-copd-3-637]; [@b118-copd-3-637]). Furthermore, relatively low limb muscle strength is a powerful predictor of mortality in severe COPD patients ([@b161-copd-3-637]).

Reduction in muscle endurance
-----------------------------

Many reports have confirmed that the endurance (defined as the capacity of the muscle to maintain a certain force over time) of limb muscles is attenuated by about 30% in patients with moderate COPD and that poor muscle endurance in these patients correlates positively with physical activity index, forced expiratory volume in one second (FEV~1~) and resting partial pressure of oxygen in arterial blood (PaO~2~) ([@b150-copd-3-637]; [@b167-copd-3-637]). [@b4-copd-3-637] have concluded that attenuation of quadriceps muscle endurance in COPD patients is related to reduced oxidative capacity of the mitochondria and to the development of oxidative stress in the muscle. Recently, this reduction of muscle endurance time has been confirmed using artificial stimulation protocols ([Figure 2](#f2-copd-3-637){ref-type="fig"}) ([@b160-copd-3-637]).

Muscle fiber atrophy
--------------------

It has been well established that limb muscles of COPD patients develop significant reductions in mass and cross-sectional areas ([@b48-copd-3-637]; [@b70-copd-3-637]). The magnitude of loss of thigh muscle mass is relatively greater than that of whole body weight, indicating a preferential loss of muscle tissue over other body tissues in emaciated COPD patients ([@b18-copd-3-637]). The degree to which fiber atrophy contributes to reduced limb muscle strength in these patients remains debatable. On one hand, several reports have described that when limb muscle strength is normalized per cross-sectional area or mass, no differences can be observed between COPD patients and control subjects ([@b18-copd-3-637]; [@b46-copd-3-637], [@b48-copd-3-637]). This conclusion is supported by the observation that *in vitro* maximum tetanic tension of vastus lateralis muscles, normalized per muscle bundle cross-sectional area, is similar in COPD patients and control subjects ([@b33-copd-3-637]). These studies clearly lend credence to the notion that muscle atrophy is the sole cause of reduced limb muscle strength and endurance in COPD patients. On the other hand, [@b106-copd-3-637] have used standard ratio, power function ratio and analysis of covariance to normalize isokinetic dynamometry parameters (peak torque, isometric strength and total work) of leg muscles to leg muscle mass and have shown that greater muscle mass is needed to generate a given functional output in COPD patients as compared with control subjects. As such, they suggest that factors other than atrophy might play a role in explaining skeletal muscle dysfunction in COPD patients ([@b106-copd-3-637]). Their position is supported by several reports that have documented the presence of intrinsic abnormalities inside limb muscle fibers of COPD patients, especially in the form of contractile fatigue ([@b104-copd-3-637], [@b105-copd-3-637], [@b102-copd-3-637], [@b103-copd-3-637]; [@b143-copd-3-637], [@b144-copd-3-637], [@b142-copd-3-637]). A good example of these reports is that of Mador and colleagues ([@b78-copd-3-637]) who found a significant decrease in quadriceps twitch force of patients with severe COPD -- by more than 20% within 30min of termination of exercise -- a value that was significantly greater than that observed in control subjects. Furthermore, [@b102-copd-3-637] have also compared the degree of fatigability in limb muscles of COPD patients and control subjects exercising at work loads designed to generate similar absolute oxygen consumption and have described significantly greater falls in quadriceps muscle twitch force in COPD patients than in control subjects, suggesting that limb muscles of COPD patients are more fatigable than those of healthy individuals.

Fiber type shift
----------------

In severe COPD patients, quadriceps muscles undergo significant redistribution of fiber type ratios, manifested as a reduction in the proportion of type I (slow-twitch oxidative) fibers and augmentation of the proportion of type IIb (fast twitch glycolytic) fibers. An early report by [@b177-copd-3-637] demonstrated that type I fiber proportion declines by 20%, whereas the proportion of type IIb fibers increases by 10% in patients with severe COPD. A subsequent study by [@b109-copd-3-637] confirmed a shift toward type II fibers and a reduction in the proportion of type I fibers in the vastus lateralis muscles of patients with severe COPD. Recent meta-analysis has revealed that the proportion of type I fibers in the vastus lateralis muscle correlates with FEV~1~, FEV~1~/forced vital capacity (FVC) and the body mass index (BMI) in patients with moderate to severe COPD ([@b62-copd-3-637]). Although the exact functional consequences of this fiber type redistribution remain under investigation, the fact that type II fibers are fatigue-prone suggests that an increased proportion of type II fibers might be an important factor in increased leg muscle fatigability and reduced endurance. It should be emphasized that fiber type shifting towards more glycolytic fibers in limb muscles of COPD patients is associated with reductions in muscle oxidative capacity, as shown by significantly lower levels of cytochrome c oxidase and succinate dehydrogenase in the quadriceps of patients with severe COPD ([@b61-copd-3-637]). In a subsequent study, [@b58-copd-3-637] have reported that reduced oxidative capacity of the quadriceps of COPD patients can be attributed, in part, to reduction in mitochondrial density in that muscle. The exact mechanisms responsible for reduced mitochondrial density in limb muscles of COPD patients are as yet unclear, however recent observations of [@b138-copd-3-637], that peroxisome proliferator-activated receptors (PPARs), PPAR-γ co-activator PGC-1α and the mitochondrial transcription factor A (TFAM) are significantly lower in quadriceps of cachectic patients with severe COPD, suggest that mitochondrial biogenesis is significantly reduced in limb muscles of these patients.

Consequences of skeletal muscle dysfunction in patients with COPD
=================================================================

Reduced exercise capacity and dyspnea on exertion are the most common complaints in patients with COPD. These symptoms cannot be explained entirely on the basis of a decline in lung function and impaired gas exchange. Indeed, [@b83-copd-3-637] measured leg effort and dyspnea in 97 patients with chronic airway obstruction during maximal cycle ergometry and concluded that the intensity of leg effort is more crucial than the degree of dyspnea. In addition, observations that considerable exercise limitation persists in COPD patients who have undergone lung transplantation, despite marked improvement in lung function, and in COPD patients that have experienced an improvement in airway obstruction by using bronchodilators, provides evidence in favor of a poor relationship between lung function and exercise performance ([@b93-copd-3-637]; [@b143-copd-3-637]). Reduced exercise capacity and limb muscle weakness lead to COPD patient disability and correlate with higher utilization of health care resources. This conclusion is supported by [@b38-copd-3-637] in their analysis of factors associated with higher utilization of health care resources in 57 stable severe COPD patients. They have shown that quadriceps muscle force alone, rather than pulmonary function and exercise capacity, is a significant determinant of higher utilization of health care resources. [@b117-copd-3-637] have reached a similar conclusion. Skeletal muscle dysfunction also contributes to poor clinical outcomes, as indicated by a significant relationship between mid-thigh cross-sectional area and mortality in stable COPD patients ([@b110-copd-3-637]).

Ventilatory muscle function
===========================

There is increasing evidence that the degree of skeletal muscle dysfunction in COPD patients is not homogenous between various muscle groups. Indeed, [@b63-copd-3-637] have found that inspiratory muscle strength is more severely reduced than that of expiratory muscle strength and that proximal upper muscle strength is more impaired than distal upper limb strength in patients with moderate COPD. Similarly, [@b52-copd-3-637] have described a relatively milder reduction in arm strength than that of leg strength, which is more severely attenuated. The reasons behind these differences between various skeletal muscles remain unclear, however many investigators have proposed that daily muscle recruitment and activation largely determines the degree to which a given muscle is affected in these patients. For instance, the ventilatory muscles, particularly the diaphragm, have different workloads than do the lower limb muscles. Ventilatory muscles are in a chronically overloaded state due to increased work of breathing brought on by airflow obstruction and hyperinflation.

In contrast, limb muscles, especially lower extremity muscles, are in a chronically underloaded state due to chronic inactivity and disuse. These dissimilar loading patterns are the likely cause of biochemical and structural adaptations that develop in the ventilatory muscles but that are not present in lower limb muscles of COPD patients. For instance, the diaphragms of patients with severe COPD have increased proportions of type I fibers as compared with control subjects. This was documented for the first time by [@b98-copd-3-637] who reported that the proportion of type I fibers averages 64% of total fibers in the diaphragms of patients with severe COPD whereas the proportion of these fibers averages only 45% of total fiber number in control diaphragms. It should be emphasized that this rise in the proportion of type I fibers in the diaphragm is evident only in severe, as opposed to moderate, COPD patients ([@b122-copd-3-637]; [@b121-copd-3-637]).

[@b100-copd-3-637] have also demonstrated that a negative exponential relationship exists between the proportion of type I fibers in the diaphragm and resting FEV~1~ (% predicted), implying that a reduction in FEV~1~ down to 60% predicted value has no influence on the proportion of type I fibers, and that a further decline in FEV~1~ is accompanied by a significant increase in the proportion of these fibers. These results suggest that diaphragm fiber type switching, to more fatigue resistant fibers, is highly dependent on the severity of the pulmonary disease process in COPD patients. Moreover, fiber type switching toward an increase in proportion of type I fibers is not limited to the diaphragm but can also be observed in other inspiratory muscles. Indeed, [@b99-copd-3-637] have reported an increase in the proportion of type I fibers, from an average of 51% in the parasternal intercostals of control subjects to 73% in the same muscles of patients with severe COPD.

Other adaptive changes that have been observed in the diaphragm of COPD patients include increased mitochondrial density, increased oxidative capacity and enhanced myosin ATPase activity ([@b122-copd-3-637]; [@b97-copd-3-637]). Additionally, relatively shorter sarcomere lengths have been measured in the diaphragms of COPD patients with hyperinflation, as compared to those without hyperinflation ([@b98-copd-3-637]; [@b122-copd-3-637]). This shortening of diaphragm sarcomeres represents an adaptive response designed to reverse the negative influence of hyperinflation on the force-length characteristics of the diaphragm that helps to preserve diaphragm fiber capacity to generate tension. It should be emphasized that despite several compensatory adaptations in the diaphragm of COPD patients, maximal strength of this muscle, as measured by maximal transdiaphragmatic pressure (Pdimax), remains about 30 to 40% lower in COPD patients as compared with control subjects ([@b17-copd-3-637]; [@b133-copd-3-637]). [@b63-copd-3-637] have also reported that inspiratory muscle strength in patients with severe COPD, as measured by maximal inspiratory pressure, averaged 59% of that measured in control subjects.

Reduction of diaphragm strength in COPD patients has been traditionally attributed to hyperinflation-induced shortening of diaphragmatic length, which has a negative influence on the pressure-length relationship. This view is supported by the observation that lung volume reduction surgery results in an increase in diaphragm length and restoration of Pdi~max~ in COPD patients ([@b92-copd-3-637]). Moreover, intrinsic abnormalities within diaphragm muscle fibers cannot be ruled out as significant contributors to the reduced strength of this muscle in COPD patients. Indeed, [@b100-copd-3-637] measured maximal isometric force of single muscle fibers obtained from the diaphragm of two severe COPD patients and reported that maximal force of type I and IIa fiber was significantly lower in these patients than in control subjects. Reduction in force generation of isolated diaphragm muscle fibers has also been documented in patients with mild to moderate COPD ([@b127-copd-3-637]). This observation cannot simply be attributed to muscle fiber atrophy and the reduction of levels of myofilament proteins since significant reduction in Ca^++^ sensitivity of skinned muscle fibers and impaired cross-bridge cycling kinetics can also be observed in the diaphragms of COPD patients ([@b127-copd-3-637]; [@b157-copd-3-637]).

Other intrinsic abnormalities in the diaphragm of COPD patients include reduced passive-tension generation of diaphragm single fibers. This condition can be attributed, in part, to selective alternative splicing of the titin gene, resulting in increased length of the elastic segment of the protein that is rich in proline, glutamate, valine, and lysine ([@b125-copd-3-637]). In addition, the diaphragms of COPD patients manifest increased susceptibility to sarcomere injuries, both at the basal level and in response to increased activation of the muscle during resistive loading ([@b123-copd-3-637]).

COPD also induces upper limb muscles to develop adaptive changes that are different from those detected in lower limb muscles. For instance, [@b55-copd-3-637] compared exercise performance, handgrip strength and metabolic profile of the deltoid muscles and found that handgrip strength changes very little in COPD patients, despite a marked reduction in exercise capacity. In addition, while deltoid muscle creatine kinase and phosphofructo-kinase activities do not differ among COPD patients and control groups, the activities of citrate synthase and lactate dehydrogenase are significantly greater in COPD patients, suggesting the presence of metabolic adapative changes in both mitochondrial oxidative capacity and glycolysis pathways ([@b55-copd-3-637]; [@b66-copd-3-637]).

Mechanisms of skeletal muscle dysfunction in COPD patients
==========================================================

Potential mechanisms of skeletal muscle dysfunction in COPD patients are summarized in [Figure 3](#f3-copd-3-637){ref-type="fig"}. Skeletal muscle dysfunction in COPD patients can be attributed to a set of complex interactions between many factors, both systemic and local.

Systemic factors
----------------

It has long been recognized that systemic factors such as inflammation, malnutrition, medication, inactivity, age, hypoxemia, and smoking exert strong effects on skeletal muscle performance in COPD patients.

Inflammation
------------

Systemic and/or local inflammation has been identified as a common feature of COPD. In stable COPD patients, elevated serum levels of C-reactive protein, fibrinogen, circulating leukocytes and pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNFα), interleukin-8 (IL8), IL6, soluble TNF receptors 55 (sTNF-R55) and 72 (sTNF-R75) have been observed ([@b147-copd-3-637]; [@b41-copd-3-637]; [@b54-copd-3-637]). Recently, significant elevations in serum IL18 have been observed in patients with moderate to severe COPD ([@b129-copd-3-637]). The cellular origins of pro-inflammatory cytokines in the serum of stable COPD patients remain unclear. One likely source is the lungs, where intense inflammatory processes develop in the vasculature, parenchyma and airways. However, no direct correlations have been found between sputum and plasma concentrations of IL8, sTNF-R55 and sTNF-R75 in patients with mild to moderate COPD ([@b173-copd-3-637]), suggesting that organs other than the lungs contribute to elevated levels of systemic inflammatory mediators. One such organ is skeletal muscle, particularly the diaphragm and intercostal muscles, where the work of breathing in COPD patients is elevated. This view is based on the observations that strenuous resistive breathing and whole body exercise in healthy humans, such as treadmill running, induce significant elevations of plasma pro-inflammatory cytokine levels, including IL6, IL-1β, and TNFα and that this production is mediated in part by increased oxygen radical production ([@b171-copd-3-637], [@b170-copd-3-637]; [@b124-copd-3-637]). This role of ventilatory muscles as a source of systemic inflammation has been confirmed in an animal model of inspiratory resistive loading, where increased work of breathing significantly upregulates IL6, IL1β and TNFα expressions within the diaphragm ([@b168-copd-3-637]). A recent study by [@b26-copd-3-637] has confirmed that TNFα and IL6 levels are significantly elevated in the intercostal muscles of COPD patients.

The involvement of inflammatory mediators in skeletal muscle dysfunction is also suggested by the observation that systemic inflammation markers correlate with poor muscle contractile performance in COPD patients. For example, quadriceps muscle strength correlates negatively with serum IL8 levels in COPD patients during exacerbation and with serum IL6 and TNFα in aged COPD patients ([@b153-copd-3-637]; [@b181-copd-3-637]). Other authors have revealed that low FEV~1~ values correlate with increased plasma levels of C-reactive protein and IL6 in severe to very severe COPD cases and that elevated C-reactive protein levels associate not only with diminished limb muscle strength but also with reduced exercise endurance and poor health status and quality of life, independent of other factors such as age, sex, and smoking history ([@b21-copd-3-637]; [@b131-copd-3-637]).

The notion that systemic inflammation contributes to skeletal muscle dysfunction in COPD patients is also supported by the fact that many pro-inflammatory cytokines can adversely influence skeletal muscle growth and contractile performance. This is particularly true with TNFα, which promotes muscle wasting by enhancing the activity of the ubiquitin proteasome pathway ([@b95-copd-3-637]). TNFα also promotes muscle wasting by inducing apoptosis ([@b25-copd-3-637]). Loss of nuclei, a result of increased apoptosis in skeletal muscle fibers, alters myonuclear domain size (the amount of cytoplasm per myonucleus), eventually resulting in muscle atrophy. The involvement of apoptosis in limb muscle wasting in COPD patients was first proposed by [@b2-copd-3-637], who described increased numbers of apoptotic nuclei in quadriceps muscles of these patients. TNFα might also reduce skeletal muscle oxidative capacity by inhibiting mitochondrial biogenesis ([@b166-copd-3-637]). Finally, TNFα exerts acute inhibitory effects on muscle contractility ([@b179-copd-3-637]), which has been attributed to depressed sensitivity of myofilament proteins to Ca^++^ and to enhanced generation of ROS and RNS ([@b137-copd-3-637]).

It should be emphasized that despite convincing documentation of elevated circulating levels of pro-inflammatory cytokines in stable COPD patients, as well as in those suffering from acute exacerbations, general agreement is lacking about the degree to which pro-inflammatory mediators are upregulated in limb muscles. On one hand, [@b15-copd-3-637] measured various pro-inflammatory cytokines in quadriceps muscles of 19 patients with severe COPD and substantial muscle atrophy and reported that IL6, IL1β, interferon-γ and TGF-β levels were not significantly different from those detected in control subjects. TNFα expression was actually lower in quadriceps muscles of COPD patients as compared with control subjects ([@b15-copd-3-637]). Similarly, [@b31-copd-3-637] failed to detect significant elevations of IL8, IL6 and TNFα in quadriceps muscles of hospitalized and clinically stable COPD patients, as compared with age-matched control subjects.

On the other hand, [@b116-copd-3-637] have described a more than fivefold increase in TNFα levels in quadriceps of patients with severe COPD, as compared with control subjects. A significant increase in NFκB nuclear binding activity (a major regulator of cytokine production) has also been observed in limb muscles of patients with severe COPD ([@b1-copd-3-637]). More recently, [@b129-copd-3-637] have described significant upregulation of IL18 in quadriceps muscle samples obtained from patients with moderate to severe COPD. The reasons behind these contradictory results are as yet unclear, but factors such as the use of relatively low numbers of patients, the presence or absence of hypoxemia, severe weight loss, exacerbation of pulmonary manifestations and the development of oxidative stress inside muscle fibers might be involved.

Malnutrition
------------

The importance of nutritional status on exercise performance and skeletal muscle dysfunction in COPD patients stems from the fact that over 30% of COPD patients undergoing pulmonary rehabilitation experience nutritional depletion (less than 90% of ideal body weight) ([@b148-copd-3-637]). Malnutrition in COPD patients is the result of an imbalance between energy intake and energy expenditure. Reduced dietary intake in these patients has been attributed to symptoms such as postprandial dyspnea, early satiety, fatigue and loss of appetite. Elevated energy expenditure has been attributed to increased work of breathing, thermogenic effects of bronchodilators and systemic inflammation ([@b6-copd-3-637]; [@b172-copd-3-637]). The reduction in body mass index in COPD patients significantly correlates with high mortality ([@b91-copd-3-637]). A clear influence of nutritional status on skeletal muscle contractile performance and structure has been documented in patients with anorexia nervosa (body mass index of less than 14) where maximum quadriceps muscle strength is significantly reduced and marked atrophy of type I and II muscle fibers is detectable ([@b112-copd-3-637]). These patients also develop substantial reduction in limb muscle oxidative and glycolytic enzyme activities.

The respiratory muscles are not immune from the effects of malnutrition, as evidenced by a reduction in inspiratory and expiratory airway pressures in cachectic COPD patients (\<80% of ideal body weight), as compared with normal weight COPD patients ([@b120-copd-3-637]). It should be emphasized that while nutritional depletion may play an important role in muscle dysfunction in COPD patients, nutritional supplementation evokes only modest improvements in muscle function, suggesting that nutritional depletion may not be the primary mechanism responsible for skeletal muscle dysfunction in COPD ([@b51-copd-3-637]).

Medication
----------

Among the many drugs used to treat COPD, corticosteroids alone are capable of eliciting skeletal muscle dysfunction (steroid-induced myopathy). Short periods of high-dose corticosteroid therapy and prolonged therapy with low-dose corticosteroids are commonly prescribed for acute exacerbations of COPD and for controlling chronic symptoms in some patients. Long-term therapy with relatively high doses of corticosteroids elicits significant reduction in strength and atrophy of both ventilatory and limb muscles of COPD patients ([@b40-copd-3-637]). [@b40-copd-3-637] also reported, in a study involving two patients with asthma and one with COPD, that prolonged administration of relatively high doses of corticosteroids elicits very severe reductions in quadriceps muscle strength and maximum inspiratory and expiratory pressures. Tapering of corticosteroid therapy improves quadriceps muscle force and inspiratory and expiratory muscle strengths.

In a subsequent study, [@b39-copd-3-637], [@b37-copd-3-637] described severe quadriceps muscle weakness, out of proportion to the loss of body muscle mass, in COPD patients taking an average daily dose of steroids (4 mg of methylprednisolone) as a short-burst therapy during acute exacerbations. Depressed muscle contractility is associated with histological evidence of fiber atrophy and necrosis ([@b37-copd-3-637]). The deleterious effects of corticosteroids on skeletal muscle function have been attributed to inhibition of signaling pathways involved in protein synthesis, as well as to augmented protein degradation, which itself is a result of increased expression and activity of the ubiquitin-proteasome pathway, including upregulation of pathway regulators known as Forkhead transcription factors. It should be noted that these studies on the influence of corticosteroid therapy on muscle function were conducted on COPD patients during acute exacerbations. To distinguish the effects of corticosteroids from other factors that may influence skeletal muscle function during acute exacerbations, [@b69-copd-3-637] reported that a 2-week course of prednisolone (30 mg) therapy in stable COPD patients did not affect quadriceps muscle strength or metabolic parameters during exercise, suggesting that, in the absence of acute exacerbation (eg, systemic inflammation or immobility), short-term corticosteroid treatment does not in and of itself cause skeletal muscle weakness.

Inactivity
----------

The fact that a great proportion of COPD patients live a sedentary lifestyle (no regular activity over a two year period) has led many investigators to attribute skeletal muscle dysfunction in these patients to physical deconditioning. Physical inactivity induces several adaptive changes in skeletal muscles, including reduced proportions of type I fibers, attenuation of oxidative enzyme capacity, regulators of mitochondrial biogenesis (PPARs and PGC-1α), fiber atrophy, reduction of antioxidant enzyme levels and lower capillary density ([@b53-copd-3-637]; [@b96-copd-3-637]; [@b138-copd-3-637]). These changes, collectively known as musculoskeletal deconditioning, result in significant reductions in skeletal muscle strength and endurance. The degree of musculoskeletal deconditioning is highly dependent on the causes and duration of inactivity, as well as on morphological and biochemical properties of skeletal muscles. While there are similar morphological, structural and biochemical abnormalities in the skeletal muscles of COPD patients and in those elicited by chronic inactivity, there is some evidence that physical inactivity alone does not sufficiently explain the skeletal muscle dysfunction seen in COPD patients. For instance, one study, in which proper control subjects had similar physical activity levels to those of COPD patients, revealed reductions of quadriceps muscle endurance in the COPD patients that cannot be explained by a mere lack of physical activity since reductions in the proportion of type I fibers in quadriceps muscles of COPD patients are relatively greater than in the control group ([@b29-copd-3-637]). Indeed, while sedentary lifestyle is associated with reduction of quadriceps muscle type I fiber proportion, from 60%--65% in healthy active control subjects to about 40% in inactive subjects ([@b134-copd-3-637]; [@b72-copd-3-637]), the proportion of type I fibers in quadriceps muscles of COPD patients reaches as low as 19% ([@b61-copd-3-637]; [@b4-copd-3-637]; [@b139-copd-3-637]). It is also worth noting that prolonged periods of exercise training exerts a relatively small influence on the proportion of type I fibers in quadriceps muscles of COPD patients, and only partially reverses reductions in oxidative enzyme activities (citrate synthase and 3-hydroxyacyl-CoA dehydrogenase) in the muscle ([@b108-copd-3-637]; [@b177-copd-3-637]).

Variant results have been published, however, regarding the precise relationship between physical activity and limb muscle endurance in COPD patients. While [@b150-copd-3-637] have described a positive correlation between quadriceps muscle endurance and physical inactivity, both [@b28-copd-3-637] and [@b59-copd-3-637] have failed to find a relationship between these parameters. These contradictory results, therefore, suggest that physical inactivity may contribute to, but does not fully explain, limb muscle dysfunction in COPD patients.

Age
---

COPD usually develops with advanced age. Accordingly, the selective effects of aging should be taken into consideration when analyzing the various factors responsible for muscle dysfunction in these patients. It has been well established that limb muscles of older individuals are significantly smaller and have significantly more fat and connective tissues than those of younger individuals ([@b101-copd-3-637]). In addition, limb muscle strength, particularly that of the quadriceps muscle, has been reported to be about 39% lower in men in their seventies as compared to men in their twenties ([@b182-copd-3-637]). Furthermore, declines in muscle strength with aging correlate with the degree of atrophy of type II fibers and are not limited to limb muscles. Indeed, maximum transdiaphragmatic pressure (Pdi~max~) measured at various lung volumes is reportedly to be approximately 25% lower in elderly subjects as compared to that measured in young subjects ([@b165-copd-3-637]). Similarly, 13% and 23% reductions in sniff Pdi and twitch Pdi (generated by phrenic stimulation) have been observed in elderly subjects, as compared to young subjects ([@b132-copd-3-637]). These studies clearly indicate that aging contributes to poor skeletal muscle contractile performance in COPD patients.

Hypoxemia
---------

Many COPD patients develop chronic moderate hypoxemia or may present with repeated episodes of hypoxemia. It has been well established that prolonged exposure to hypobaric hypoxia is associated with significant reductions in skeletal muscle strength and endurance, increases in muscle atrophy and attenuation of mitochondrial Krebs cycle enzyme activity ([@b71-copd-3-637]; [@b24-copd-3-637]). Although there is no direct proof of the involvement of hypoxemia in reduced skeletal muscle strength and endurance in COPD patients, there is circumstantial evidence that suggests that hypoxemia may contribute to the deterioration of skeletal muscle performance. For instance, the proportions of type I fibers in quadriceps muscles are significantly lower in hypoxemic COPD patients as compared to nonhypoxemic COPD patients ([@b61-copd-3-637]).

Moreover, exercise endurance in COPD patients ([@b150-copd-3-637]). Jakobsson correlates positively with PaO~2~ and colleagues [@b76-copd-3-637] have reported that adenosine tri-phosphate (ATP), glycogen and creatine phosphate levels in quadriceps muscle fibers are significantly reduced in COPD patients with chronic respiratory failure as compared to those without respiratory failure and they described a significant correlation between muscle metabolites and arterial PO~2~. Moreover, chronic hypoxemic COPD patients show greater levels of exercise-induced lipid peroxidation and oxidized proteins in their quadriceps muscles than do nonhypoxemic COPD patients ([@b89-copd-3-637]). As with the case of lower limb muscles, maximum diaphragm force and diaphragm endurance are both significantly reduced in COPD patients with chronic hypoxemia, although inhalation of O~2~ for 15min elicits an increase in diaphragm strength and endurance ([@b183-copd-3-637]).

Hypoxemia can elicit skeletal muscle dysfunctions through direct and indirect actions on contractile processes. The acute and direct inhibitory effects of hypoxia on skeletal muscle contractile performance have been demonstrated in several *in vitro* experiments utilizing rat diaphragm strips ([@b151-copd-3-637]). While these experiments might explain the decline in limb muscle and diaphragm strength in severe COPD patients, the mechanisms responsible for the relationship between hypoxemia and fiber type redistribution and alterations in the metabolic profiles of skeletal muscles remain unclear. Indirect inhibitory effects of hypoxemia on skeletal muscle function are mediated mainly through the release of pro-inflammatory cytokines such as TNFα and IL1β ([@b56-copd-3-637]). This notion is supported by the observations that circulating levels of TNFα and soluble TNFα receptors in COPD patients are significantly higher than in control subjects and that these levels are inversely ([@b162-copd-3-637]). related to PaO2

Smoking
-------

Most COPD patients are current or previous smokers, making smoking the main risk factor for COPD. However, the potential effects of smoking on skeletal muscle function remain unclear. A recent study by [@b115-copd-3-637] suggests that smoking *per se*, independent of the presence of COPD, elicits skeletal muscle atrophy, as indicated by a reduction in the cross-sectional areas of both type I and II fibers, a reduction in the expression of constitutive nitric oxide synthases and augmentation of the number of low oxidative and highly glycolytic muscle fibers. The deleterious effects of smoking on muscle metabolism have been further analyzed by [@b128-copd-3-637], who have reported that heavy smoking (≥20 cigarettes/day for ≥20 years) elicits no change in whole body protein breakdown but significantly attenuates quadriceps muscle protein synthesis and augments the expression of both myostatin (inhibitor of muscle growth) and atrogin-1 (E3 ligase). These results suggest that smoking induces skeletal muscle fiber atrophy as a result of inhibition of protein synthesis, rather than as a result of increased protein degradation. These deleterious effects of smoking on skeletal muscle function may be mediated directly by nicotine or by other toxic byproducts of cigarette smoke, or indirectly as a result of changes in lifestyle and physical activity.

Local factors
-------------

Skeletal muscle dysfunction in COPD patients has also been attributed to local factors within skeletal muscle fibers that may elicit Specific changes in protein expression and function, eventually resulting in reduction of muscle mass and depressed contractile functions. These factors include oxidative and nitrosative stress of muscle fibers and changes in the balance between protein synthesis and degradation.

Oxidative and nitrosative stress
--------------------------------

Both ROS and RNS species are highly reactive molecules normally produced at relatively low levels inside skeletal muscle fibers. ROS are derived from superoxide anion (O~2~ ^•−^) while RNS are derived from nitric oxide (NO^•^). In normal skeletal muscle fibers, ROS are produced at relatively low levels and play a positive role in maintaining muscle contractility ([@b136-copd-3-637]). However, increased production of these species, to levels significantly greater than those that can be neutralized by intracellular antioxidant defenses, leads to the development of a state of oxidative stress, which has profound effects on action potential conduction, excitation--contraction coupling, contractile proteins, and mitochondrial respiration ([@b136-copd-3-637]).

NO^•^ is formed from L-arginine by nitric oxide synthases (NOSs). Three distinct NOS isoforms have been identified: neuronal (nNOS) and endothelial (eNOS), which are constitutively expressed in many cell types; and inducible NOS (iNOS), which is induced by pro-inflammatory cytokines ([@b44-copd-3-637]; [@b154-copd-3-637]). In normal mammalian skeletal muscles, a special form of nNOS (nNOSμ) is expressed close to the sarcolemma and musculo-tendon junction ([@b86-copd-3-637]; [@b20-copd-3-637]) whereas the eNOS isoform is expressed inside the mitochondria of mature muscles ([@b87-copd-3-637]). iNOS is induced inside the cytosol of skeletal muscles in septic humans and other animals and in cultured myoblasts exposed to inflammatory cytokines. Constitutive NO production inside skeletal muscle fibers modulates glucose transport and insulin-mediated skeletal muscle vasodilation ([@b155-copd-3-637]; [@b9-copd-3-637]; [@b8-copd-3-637]; [@b82-copd-3-637]; [@b140-copd-3-637]). In addition, NO promotes vasodilation of skeletal muscle vasculature by acting directly on smooth muscles ([@b75-copd-3-637]), whereas NO synthesized within the muscles, nNOS, promotes vasodilation of muscle vessels by inhibiting sympathetic vasoconstriction ([@b163-copd-3-637]; [@b164-copd-3-637]).

In contrast to the regulatory roles that physiological levels of ROS and RNS play inside skeletal muscle fibers, excessive levels of ROS and RNS provoke a diverse array of deleterious effects that are attributed to peroxidation of membrane phospholipids, carbonyl formation and nitration of tyrosine residues. Peroxidation of membrane lipids leads to the fragmentation of polyunsaturated fatty acids, resulting in the production of various cytotoxic and highly reactive aldehydes, alkenals, and hydroxyalkenals such as malonaldehyde (MDA) and 4-hydroxy-2-nonenal (HNE) ([@b65-copd-3-637]). In comparison, carbonyls are formed as a result of oxidation of the amino acids arginine, lysine, threonine, and proline ([@b32-copd-3-637]). As yet, the influence of tyrosine nitration on muscles has not been fully uncovered, although it is known to adversely affect protein function and is linked to severity status of COPD in both acute and chronic situations ([@b116-copd-3-637]).

The development of oxidative and nitrosative stress has been documented in the plasma, urine and skeletal muscles of COPD patients, both at rest and following exercise. In patients with severe COPD, urinary MDA levels, and H~2~O~2~ concentrations in breath condensate are significantly higher than those measured in control subjects ([@b113-copd-3-637]). In resting quadriceps muscles of patients with severe COPD, total glutathione concentrations are lower whereas the levels of HNE and lipofuscin (products of lipid peroxidation) are significantly higher than those detected in control subjects ([@b46-copd-3-637]; [@b5-copd-3-637]; [@b11-copd-3-637]). In addition, resting limb muscles of COPD patients have increased protein tyrosine nitration and elevated levels of iNOS protein, suggesting the development of nitrosative stress ([@b11-copd-3-637]; [@b116-copd-3-637]). With respect to exercise, patients with moderate to severe COPD have elevated ROS-induced DNA damage in peripheral blood mononuclear cells, plasma uric acid, blood oxidized glutathione and lipid peroxides levels at the end of whole body exercise indicating that these patients experience systemic oxidative stress, even during normal daily activity ([@b174-copd-3-637]; [@b67-copd-3-637]; [@b113-copd-3-637]). [@b29-copd-3-637] have proposed that exercising limb muscles might be an important source of ROS products released into the plasma of COPD patients. This is supported by observations that carbonyl formation and lipid peroxidation increase significantly in quadriceps muscles of patients with severe COPD ([@b30-copd-3-637]).

In contrast to the amount of research using the quadriceps muscle, little information is yet available regarding alterations in the redox status of the diaphragm in COPD patients. [@b10-copd-3-637] were the first to report that carbonyl and HNE-protein adducts were significantly elevated in the diaphragms of patients with severe COPD ([Figure 4](#f4-copd-3-637){ref-type="fig"}). At the same time, these authors found no rise in protein tyrosine nitration in the diaphragms of patients with severe COPD. A more recent study by [@b178-copd-3-637] failed to detect a rise in lipid peroxidation in the diaphragms of patients with moderate and severe COPD patients. These contradictory results are likely due to the relatively low number of diaphragm samples that were examined and to differences in the methodologies that were used to evaluate oxidant and antioxidant levels. So, despite clear evidence of the development of oxidative stress in limb muscles of COPD patients, the contribution of oxidative stress to the contractile dysfunction of these muscles remains under investigation, although indirect evidence supports a strong role for oxidative stress in depressed skeletal muscle strength and endurance.

Targets of ROS and RNS in skeletal muscles
------------------------------------------

ROS and RNS influence skeletal muscle contractile performance by targeting several enzymes involved in mitochondrial respiration, glycolysis and Ca^++^ flux. It has long been recognized that complex I, II, and IV of the mitochondrial respiratory chain are particularly sensitive to the inhibitory effects of ROS and RNS ([@b27-copd-3-637]; [@b119-copd-3-637]). Other targets in the mitochondria include Krebs cycle oxidative enzymes such as aconitase, which is inhibited and degraded when exposed to H~2~O~2~ and O~2~ ^•−^([@b22-copd-3-637]). Creatine kinase (CK) is another target of ROS and RNS inside quadriceps muscles of COPD patients ([@b13-copd-3-637]). Others have confirmed that CK is sensitive to ROS generation during skeletal muscle fiber injury ([@b130-copd-3-637]) and is also target of peroxynitrite and lipid peroxidation products ([@b81-copd-3-637]; [@b45-copd-3-637]). In quadriceps muscles of COPD patients, the activity of CK is inversely related to the intensity of carbonylation of this protein, suggesting that CK activity is inhibited in these muscles ([@b13-copd-3-637]).

Enzymes involved in glycolysis are also targeted by both ROS and RNS inside skeletal muscles. These enzymes include enolase, aldolase and glyceraldehyde 3-phosphate dehydrogenase, which are strongly carbonylated, HNE-modified and tyrosine nitrated within the diaphragm ([@b12-copd-3-637]; [@b74-copd-3-637]; [@b169-copd-3-637]). These modifications are likely to inhibit their activities ([@b152-copd-3-637]; [@b12-copd-3-637]; [@b74-copd-3-637]; [@b169-copd-3-637]). However, whether or not the inhibitory effects of ROS and RNS on glycolytic enzymes are sufficient to alter glucose metabolism of skeletal muscle fibers remains to be investigated. Other proteins modified by ROS and RNS inside skeletal muscles include Na^+^/K^+^ pump ([@b90-copd-3-637]), Ca^++^ ATPase ([@b175-copd-3-637]; [@b85-copd-3-637]) and ryanodine receptor channels (RyR) ([@b158-copd-3-637]). Finally, ROS and RNS might also target several myofibrillar proteins including actin, myosin heavy chain and light chain, tropomyosin, γ-actin and actinin ([@b114-copd-3-637]; [@b84-copd-3-637]; [@b81-copd-3-637]; [@b169-copd-3-637]). Modifications of these proteins by ROS and RNS lead to alterations in function, changes in Ca^++^ and increased degradation.

Molecular sources of ROS and RNS
--------------------------------

Although detailed mechanisms behind the development of oxidative stress in skeletal muscles of COPD patients remain under investigation, conventionally the process has been attributed to an imbalance between the rate of oxidant production and the levels of antioxidant defenses.

Mitochondria
------------

The mitochondria are major sites of intracellular ROS production as 5% of molecular O~2~ is reduced to O~2~^−\ •^ as a result of electron leaks from the respiratory chain. Two findings suggest that mitochondrial membrane potentials might be abnormally elevated in limb muscles of COPD patients and might trigger an increase in ROS production. [@b146-copd-3-637] have reported that cytochrome c oxidase activity (complex IV) is significantly increased in quadriceps muscles of COPD patients with respiratory failure. However, because the expression of 12S ribosomal RNA (biomarker of mitochondrial biogenesis) is also increased in these patients, it is unclear as to whether the observed rise in cytochrome c oxidase activity is due to increased mitochondrial number or genuine augmentation of cytochrome c oxidase activity in a given mitochondrion, or both. Additionally, [@b60-copd-3-637] and [@b141-copd-3-637] have shown that the expression of uncoupling protein 3 (UCP3, uncouples oxidative phosphorylation from mitochondrial membrane potentials) is significantly reduced in quadriceps muscles of COPD patients. Although attenuation of UCP3 is likely to trigger augmentation of mitochondrial ROS production, direct measurements of this production in limb and ventilatory muscles of COPD are clearly required to elucidate the contribution of mitochondrial sources to overall ROS production.

Xanthine oxidase
----------------

Under physiological conditions, hypoxanthine and xanthine are oxidized to uric acid by xanthine dehydrogenase, however, under hypoxic or ischemic conditions, xanthine dehydrogenase is converted to xanthine oxidase, which preferentially reduces molecular O~2~ to O~2~^−•^ and H~2~O~2~ ([@b49-copd-3-637]). During exercise, both hypoxia and increased levels of xanthine and hypoxanthine inside skeletal muscle fibers cause significant elevation of xanthine oxidase activity. As in the case of mitochondrial ROS production, little direct evidence of increased xanthine oxidase in skeletal muscles of COPD has been published thus far, although [@b67-copd-3-637] have reported that pre-treatment with the xanthine oxidase inhibitor allopurinol significantly attenuates exercise-induced elevation of plasma oxidized glutathione and MDA levels in patients with COPD who have performed incremental exercise. Whether or not allopurinol treatment attenuates oxidative stress inside muscle fibers of exercising muscles remains unclear.

NADPH oxidase
-------------

NADPH oxidase is an enzyme complex first described in phagocytes, where it consists of four essential subunits (p22^phox^, gp91^phox^ (Nox2), p47^phox^ and p67^phox^) and two additional subunits (p40^phox^ and Rac2). NADPH oxidase is also expressed in nonphagocytes where it produces ROS under basal conditions but, upon stimulation, ROS are produced intracellularly at much lower levels than they are in phagocytes. Recent studies have confirmed the presence of Nox2, p47^phox^, p67^phox^ and p22^phox^ subunits in skeletal muscle samples and have implicated these subunits in the regulation of Ca^++^ influx and insulin signaling ([@b68-copd-3-637]; [@b77-copd-3-637]; [@b50-copd-3-637]; [@b176-copd-3-637]). These studies clearly suggest that NADPH oxidase-derived ROS play important physiological roles in regulating skeletal muscle signaling. On the basis of these results, one would not expect that a mild to moderate augmentation of muscle-derived NAPDH oxidase activity would contribute to the development of oxidative stress in skeletal muscles of COPD patients. In comparison, neutrophil- and macrophage-derived NADPH oxidases are more likely to generate pathological levels of ROS that elicit oxidative stresses in skeletal muscles. However, there is little evidence that significant neutrophil and macrophage infiltration develops in skeletal muscles of COPD patients. In fact, normal numbers of inflammatory cells have been detected in the vastus lateralis muscles of patients with COPD ([@b59-copd-3-637]).

Nitric oxide synthases
----------------------

Muscle redox state is strongly influenced by NO production, since increased NO levels in the presence of enhanced O~2~^−•^ levels leads to the production of the highly reactive peroxynitrite. Few studies have as yet explored whether or not NO production and NOS expression are altered in skeletal muscles of COPD patients. Several studies have reported that the levels of nNOS and eNOS proteins in quadriceps of patients with severe and moderate COPD are similar or even lower than that those of control subjects ([@b11-copd-3-637], [@b14-copd-3-637]; [@b116-copd-3-637]). In comparison, others described induction of the iNOS isoform in quadriceps of patients with severe COPD patients, particularly those with low BMI ([@b1-copd-3-637]; [@b116-copd-3-637]; [@b14-copd-3-637]). In addition, elevated protein tyrosine nitration in quadriceps muscles of COPD patients has been documented by many authors thereby confirming an increase in peroxynitrite formation in these patients ([@b11-copd-3-637]; [@b1-copd-3-637]; [@b116-copd-3-637]). It is worth noting that not all skeletal muscles of COPD patients show evidence of nitrosative stress and peroxynitrite formation. For instance, [@b10-copd-3-637] found no significant differences in protein tyrosine nitration, despite the presence of elevated protein carbonylation and 4HNE-protein adduction formation, in the diaphragms of patients with moderate and severe COPD. In fact, the production of NO in the diaphragms of these patients might have been even lower than in normal subjects, as indicated by the presence of lower eNOS protein levels ([@b10-copd-3-637]). Thus, while oxidative stress develops in the diaphragms of patients with COPD, there is little evidence that nitrosative stress also develops in that muscle.

The development of oxidative stress in skeletal muscles of COPD patients has also been attributed to reduction in anti-oxidant capacity. Early reports suggest that plasma levels of nonenzymatic antioxidants are significantly lower in COPD patients, both at rest and after localized exercise, than they are in control subjects ([@b135-copd-3-637]; [@b29-copd-3-637]). Measurements of protein levels and activities of antioxidant enzymes reveal that in patients with severe COPD patients and significant muscle wasting, Mn-SOD and glutathione-S-transferase activities in resting quadriceps muscles are significantly elevated ([@b57-copd-3-637]; [@b14-copd-3-637]). However, the levels of Mn-SOD, catalase, heme oxygenase-1 and glutathione peroxidase (an important enzyme in the metabolism of glutathione) in the quadriceps muscles and diaphragms of patients with moderate COPD are not different from control subjects ([@b30-copd-3-637]; [@b11-copd-3-637], [@b10-copd-3-637], [@b14-copd-3-637]).

Despite similarities in antioxidant enzyme levels, the response of these enzymes to increased oxidant production elicited by exercise or exercise training appears to be abnormal. Indeed, [@b30-copd-3-637] have reported that glutathione peroxide activity in quadriceps muscles of patients with moderate COPD remains unchanged from resting values following localized quadriceps muscle endurance exercise, while the activity of the same enzyme rises significantly in control subjects. A similar lack of augmentation of Mn-SOD activity in response to endurance training of quadriceps muscles has been observed in patients with moderate COPD ([@b14-copd-3-637]). These results suggest that exercise-induced oxidative stress does indeed develop in limb muscles of COPD patients, in part as a result of an inability of antioxidant enzymes to respond to increased oxidant production.

Regulation of protein synthesis/degradation
-------------------------------------------

Regulation of muscle mass is a dynamic process involving a delicate balance between hypertrophic (protein synthesis) and atrophic (degradation) signalling pathways. There are four classes of proteolytic enzymes that are involved in protein degradation inside skeletal muscles. In different models of muscle wasting there is coordinated stimulation of these systems, which include the proteasomal and the lysosomal pathways, calpains and caspases. Proteins targeted for degradation go through several steps, the first of which involves the activation of ubiquitin by E1 ubiquitin-activating proteins and then a transfer of activated ubiquitin to E2 ubiquitin conjugating enzymes and, finally, eventual transfer of ubiquitin to the targeted proteins. Two muscle-Specific E3 ligases, namely, muscle ring finger (MuRF1) and muscle atrophy F-box (MAFbx or atrogin-1) have recently been cloned and have been shown to be significantly induced inside muscle fibers in various models of muscle atrophy, including denervation, immobilization and fasting ([@b19-copd-3-637]). Upstream signals that mediate the activation of the ubiquitin--proteasome pathway in skeletal muscle atrophy remain unclear. However, recent studies have indicated that expressions of atrogin-1 and MuRF1 are controlled by a complex signaling network comprised of the FoxO transcription factors ([@b145-copd-3-637]) and their upstream regulators, including protein kinase B (AKT) ([@b23-copd-3-637]).

The second step involves the lysosomal system, which consists of several cathepsins (acid hydrolases), glycosidases, lipases, nucleases and phosphatases, and is responsible for degradation, through autophagy, of most membrane and extracellular proteins taken up by endocytosis, in addition to cytoplasmic proteins and organelles ([@b149-copd-3-637]). Calpains consist of fourteen different cysteine pro-teases that are dependent on Ca^++^. Skeletal muscles contain substantial levels of two ubiquitous calpains, one that requires micromolar concentrations of Ca^++^ (μ-calpain), and one that requires millimolar levels of Ca^++^ (m-calpain), in addition to the calpain inhibitor calpstatin ([@b16-copd-3-637]). Calpains cleave proteins at selective sites and are not involved in the degradation of cytosolic proteins inside skeletal muscles. Finally, caspases are responsible for degrading cellular proteins during apoptosis and many recent reports have documented increases in caspase activity and/or expression inside skeletal muscles in a variety of pathological conditions, including muscular dystrophy, sepsis and exercise-induced oxidative stress ([@b159-copd-3-637]; [@b73-copd-3-637]; [@b88-copd-3-637]). Although it is known that caspase-3 acts upstream from the proteasomal pathway and that it is capable of degrading actin in *in vitro* settings ([@b43-copd-3-637]), the exact contributions of caspases to *in vivo* skeletal muscle protein degradation remain unclear.

It is generally assumed that peripheral muscle atrophy in patients with COPD is due to an imbalance between protein synthesis and degradation, in favor of the latter ([@b34-copd-3-637]). However, the precise contributions of each step of the proteolysis pathway to peripheral muscle atrophy in COPD patients remains unclear. [@b36-copd-3-637] have shown that limb muscle atrophy in COPD patients may be due to an increase in the ratio of catabolic factors (IL6 and cortisol) to anabolic factors (testosterone, dehydroepiandrosterone and insulin-like growth factor-1 \[IGF-I\]). Increased IL6, ROS and RNS levels are expected to upregulate the ubiquitin-proteasome components, while increased anabolic factors are expected to downregulate these components. In a very recent study, [@b35-copd-3-637] employed microarray technology to compare gene expression profiles in quadriceps muscles of four patients with moderate or severe COPD to those of control subjects. They reported significant upregulation of FoxO1 and FoxO3 transcription factors in quadriceps muscles of COPD patients. Both transcription factors promote muscle atrophy through inhibition of IGF-I-mediated muscle growth and by upregulating the expression of atrogin-1 and MuRF-1 ([@b145-copd-3-637]; [@b156-copd-3-637]). In another study, [@b42-copd-3-637] confirmed that FoxO1 mRNA and protein and atrogin-1 and MuRF-1 mRNA expressions are significantly upregulated in quadriceps muscles of COPD patients, suggesting that the activity of the proteasomal pathway is enhanced in limb muscles of these patients ([Figure 5](#f5-copd-3-637){ref-type="fig"}). This observation cannot be explained by removal of the inhibitory effect of protein kinase B (AKT) on FoxO1 activity since AKT activity is significantly greater in quadriceps muscles of COPD patients than it is in control subjects ([@b42-copd-3-637]). It is possible that observed upregulations of FoxO1, atrogin-1 and MuRF-1 levels are due to increased activity of NFκB transcription, which is known to positively modulate the proteasomal pathway inside skeletal muscle ([@b23-copd-3-637]).

Activation of the ubiquitin-proteasomal pathway is not limited to the limb muscles of COPD patients. Activity of the 20S proteasome and atrogin-1 expression have recently been shown to be upregulated by 3-fold in the diaphragms of patients with mild to moderate COPD ([@b126-copd-3-637]). While these studies imply that the proteasomal pathway contributes to proteolysis of skeletal muscle proteins in COPD patients, no information is as yet available about the relative contributions of the lysosomal, calpain and caspase pathways to the atrophy process. Systematic and thorough investigations of how, where, and when these pathways are activated, and thus contribute to muscle protein degradation, are clearly needed in relation to patients with COPD.

To further explore the functional importance of FoxO transcription factors in regulating muscle protein degradation in COPD patients, for the present study the dataset of [@b35-copd-3-637] was analyzed using Ingenuity Pathway Analysis software (<http://www.ingenuity.com/>) to show that three major networks link the majority of significantly regulated genes in the quadriceps muscles of COPD patients. [Figure 6](#f6-copd-3-637){ref-type="fig"} shows the top network uncovered by this analysis. This network contains several highly connected nodes, such as FoxO1 and FoxO3, as well as NFκB transcription factors and two signaling pathways related to mitogen activated protein kinases, namely, the Erk1/2 and p38 pathways. Network analysis suggests that elevated expression and/or activation of FoxO1, FoxO3 and NFκB transcription factors in quadriceps muscles of COPD patients might be due to both abnormalities in the insulin pathway and attenuation of FHL2 expression.

FHL2 (four-and-a-half LIM only protein 2) is a member of a family of proteins containing the LIM domain, a conserved cysteine-rich module that plays several important roles as an adaptor or as a scaffold to support the assembly of multimeric protein complexes ([@b80-copd-3-637]). In skeletal muscles, FHL2 promotes differentiation of myoblasts into myotubes ([@b111-copd-3-637]) and functions as an adaptor molecule that links the metabolic enzymes creatine kinase, adenylate cyclase and phosphofructokinase to titin, a protein that plays a crucial role as organizer of the sarcomere ([@b94-copd-3-637]). In addition, FHL2 directly interacts with FoxO1 and suppresses its transcriptional activity ([@b180-copd-3-637]). Furthermore, deletion of FHL2 augments TRAF6-dependent NFκB activity, suggesting that a role of FHL2 is to attenuate NFκB activity ([@b7-copd-3-637]). The fact that FHL2 expression is significantly downregulated in quadriceps muscles of COPD patients raises the possibility that the increased activities of FoxO1, FoxO3 and NFκB transcription factors might be due to attenuation of the inhibitory effects of FHL2 on the activity and/or expression of these factors ([@b35-copd-3-637]). This network analysis also suggests that FoxO1 and FoxO3 transcription factors may be involved in regulating the expression of UCP2 and troponin C in muscles in these patients ([Figure 6](#f6-copd-3-637){ref-type="fig"}). Clearly, additional studies are required to fully elucidate the functional roles, not only of FoxO and NFκB transcription factors, but also of all factors related to the FHL2 and insulin pathways in mediating skeletal muscle dysfunction.

Vascular density and capillarization
------------------------------------

Little information is available about changes in capillary density in skeletal muscles of COPD patients. An initial study by Jobin and colleagues confirmed that capillary to muscle fiber ratios in the vastus lateralis muscle of patients with severe COPD are about 47% lower than those measured in the same muscle of age-matched control subjects ([@b79-copd-3-637]). A subsequent study by the same group reported relatively smaller reductions in the capillary to fiber ratio in the muscles of patients with mild to moderate COPD ([@b177-copd-3-637]). Reduction in capillary density is thought to have a deleterious effect on muscle oxidative capacity. This is indeed the case in limb muscles of COPD patients, where the activities of citrate synthase and 3-hydroxyacyl coenzyme A dehydrogenase (markers of oxidative capacity) are significantly reduced ([@b107-copd-3-637]). The decline in the activity of citrate synthase is proportional to the deterioration of functional status of the muscle ([@b107-copd-3-637]). However, because total muscle mitochondrial density is significantly reduced in COPD patients ([@b58-copd-3-637]), it is unclear whether or not the observed reduction in oxidative enzyme capacity is due to attenuation of total mitochondrial number and/or to Specific defects in the activity of these enzymes. It should be emphasized that reduction in skeletal muscle mitochondrial density in COPD patients is muscle-Specific; it has been described in the vastus lateralis muscle but not in the tibialis muscle ([@b58-copd-3-637]). Attenuation of capillary and mitochondrial densities in skeletal muscles of COPD patients is associated with augmentation of serum and muscle lactic acid levels during exercise and an early onset of contractile fatigue ([@b108-copd-3-637]; [@b47-copd-3-637]).

The precise mechanisms behind reduction in capillary density in limb muscles of COPD patients are not clear. Very recently, [@b15-copd-3-637] have reported that vascular endothelial growth factors (VEGF) protein levels in the vastus lateralis of patients with moderate and severe COPD are significantly lower than those of control subjects. These observed reductions in VEGF levels cannot be explained by inactivity or fiber type switching since no relationship was found between VEGF muscle levels and exercise tolerance parameters or fiber type distribution ([@b15-copd-3-637]). Expression of VEGF in the vastus lateralis muscles of COPD patients contrasts with that expressed in the diaphragm, which shows mildly, but significantly, elevated VEGF levels in patients with moderate COPD ([@b3-copd-3-637]). It should be noted that upregulation of VEGF expression in the diaphragms of COPD patients, which is not paralleled by an increase in fibroblast growth factor-1 and TGFβ expressions, cannot be attributed to increased mechanical loads in these patients, although other local factors such as fiber type remodeling and hypoxemia may be involved. The involvement of pro- and anti-angiogenesis factors other than VEGF in the regulation of skeletal muscle capillary density in COPD patients remains to be explored.

Summary
=======

In this review, we have collected evidence indicating that both strength and endurance of skeletal muscles in general, and limb muscles in particular, are reduced in patients with COPD and that these abnormalities are associated with attenuated exercise capacity and increased mortality. Examinations of muscle biopsies in COPD patients reveals that lower limb muscles in particular undergo Specific structural and functional alterations that are similar, but not identical, to those found in muscles that are atrophied as a result of denervation or disuse. More recent studies support the notion that, in addition to disuse/de-conditioning-induced atrophy, skeletal muscle dysfunctions in COPD patients might be due to myopathy triggered by systemic factors, including inflammation, nutritional depletion, corticosteroid use, chronic inactivity, age, hypoxemia, and smoking, and local factors due to selective increases in reactive oxygen and nitrogen species production, enhanced proteolysis, and changes in vascularization. Further studies are required to identify the precise molecular mechanisms responsible for skeletal muscle dysfunction in COPD patients.
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![**A**) Group mean values (±SD) for strength of quadriceps, pectoralis major and latissimus dorsi muscles obtained from normal subjects and COPD patients. Note significant reduction in strength in each of three muscle groups in patients with COPD, as compared to normal subjects. \*P \< 0.05. **B** ) Relationship between FEV~1~ (percentage of predicted) and quadriceps muscle strength showing significant positive relationship (r = 0.55, p \< 0.0005) Copyright © 1998. Adapted from [@b18-copd-3-637]. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 158:629--34.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second.](copd-3-637f1){#f1-copd-3-637}

![Force decline of quadriceps femoris muscle during repetitive magnetic stimulation of femoral nerve in control subjects and COPD patients. The curves were significantly different at 10, 20, 30, and 40 trains Copyright © 2007. Adapted from [@b160-copd-3-637]. A novel technique for nonvolitional assessment of quadriceps muscle endurance in humans. *J Appl Physiol*, 103:739--46.\
**Abbreviation:** COPD, chronic obstructive pulmonary disease.](copd-3-637f2){#f2-copd-3-637}

![Proposed mechanisms of skeletal muscle dysfunction in COPD patients.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; UPP, ubiquitin/proteasomal pathway.](copd-3-637f3){#f3-copd-3-637}

![**A**) Representative examples of protein oxidation (total carbonyl groups) in diaphragms of control subjects and patients with moderate and severe COPD. **B**) Mean values ± SD of total carbonyl formation higher in the patients with severe COPD, compared to control subject muscles (\*p = 0.05). No difference in total diaphragmatic carbonyl formation between patients with moderate COPD and control subjects (ns = nonsignificant). Among overall patients with COPD, optical densities of total carbonyl group formation significantly correlated with FEV~1~ (% predicted). Note that 14 COPD patients are depicted (two mild, six moderate, six severe) in correlation graph. Patients with moderate COPD have FEV~1~ and FVC of 62 ± 4 and 72% ± 11% of predicted, respectively. Patients with severe COPD have FEV~1~ and FVC of 42 ± 7 and 54% ± 9% of predicted, respectively. Copyright © 2005. Adapted from [@b10-copd-3-637]. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 171:1116--24.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity.](copd-3-637f4){#f4-copd-3-637}

![**A**) Atrogin-1 mRNA expression; **B**) MuRF1 mRNA expression; **C**) representative Western blot for atrogin-1; **D**) atrogin-1 protein expression, all from quadriceps muscles of control subjects and COPD patients. Expression data relative to control values and presented in AU. mRNA data normalized for RPLPO, cytoplasmic protein contents normalized for α-tubulin. **E**) Significant correlation between atrogin-1 and MuRF1 mRNA expressions (r2 = 0.84; p \< 0.001) in COPD patients. Values are mean ± SEM; \*p \< 0.05; ^+^p \< 0.001. Copyright © 2007. Adapted from [@b42-copd-3-637]. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 176:261--9.\
**Abbreviations:** AU, atomic units; COPD, chronic obstructive pulmonary disease; MuRF1, muscle-Specific RING finger protein 1; mRNA, messenger ribonucleic acid; RPLPO, large ribosomal protein; SEM, standard error of mean.](copd-3-637f5){#f5-copd-3-637}

![Top network of upregulated genes in quadriceps muscles of COPD patients, compared with control subjects. Figure created with Ingenuity Pathway Analysis System of microarray data from [@b35-copd-3-637]. Microarray data set used as an input file with RMA (robust multiarray analysis) threshold of 1.2 to specify upregulated genes. Filled nodes indicate upregulated genes in COPD patients. Empty nodes designate genes not detected by microarray data. Straight lines indicate direct relation while interrupted lines suggest indirect interactions.\
**Abbreviations:** AK1, adenylate kinase 1; ALDH2, aldehyde dehydrogenase 2 family, mitochondrial; COPD, chronic obstructive pulmonary disease; ERK, extracellular signal-regulated kinase; FHL2, four and half LIM domains 2; FHL3, cysteine and glycine-rich protein 3; FOXO1, forkhead box O1A (FKHR); FOXO3, forkhead box O3A (FKHRL1); FOX06, forkhead box 06; G0S2, putative lymphocyte G0/G1 switch gene; KLF9, Kruppel-like factor 9; NFκB, nuclear factor of kappa light polypeptide; P38MAPK, p38 mitogen-activated protein kinase; PDGF-BB, platelet-derived growth factor BB; SAA1, serum amyloid A1; SLC16A3, solute carrier family 16 (monocarboxylic acid transporters), member 3; T3-TR-RXR, T3-thyroid hormone receptor-retinoid X receptor complex; TMSB4X, thymosin beta 4, X-linked; TNNC1, slow troponin C; VIM, vimentin; UCP2, uncoupling protein 2, mitochondrial, proton carrier.](copd-3-637f6){#f6-copd-3-637}
